Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: Tadsamillionaire who wrote (173)	8/28/2003 12:35:07 AM
From: Tadsamillionaire	Respond to of 255

AERx® iDMS (NN1998) Indication: Type 1 and 2 diabetes Phase: Phase 3 A pulmonary delivery system for the administration of insulin by inhalation. AERx® iDMS is being developed for the treatment of diabetes in collaboration with Aradigm Corporation. The AERx system includes a breath guidance system that guides patients to breathe optimally and reproducibly. Only when breathing is correct is the drug automatically administered. This feature is not found in any other technology and is the subject of several Aradigm patents. Importantly, the technology developed by Aradigm uses strips with insulin in liquid form and not in powder form as is the case with the technology from Inhale. This makes dose adjustment possible to the nearest unit just as with injections - something that does not appear to be possible with powders. The mean system efficiency/bioeffectiveness for the AERx system in studies involving patients with type 1 and type 2 diabetes has been shown to range between 13 and 17%, depending on the study design. Visit Aradigm at www.aradigm.com novonordisk.com

To: Tadsamillionaire who wrote (173)	8/28/2003 12:09:56 PM
From: Numberspro	Read Replies (1) \| Respond to of 255

It seems that Bristol Myers and Flamel are also addressing the issue. See FLML. Thanks for the info. France's Flamel Technologies (FLML:Nasdaq - commentary - research) was bid up sharply in premarket trading after Bristol-Myers (BMY:NYSE - commentary - research) anointed a diabetes treatment it's developing. The companies entered a licensing and commercialization agreement covering Flamel's Basulin, a controlled-release form of insulin that is about to enter phase II clinical trials. The agreement calls for Bristol-Myers to assume the cost of future development and manufacturing of the drug, in return for exclusive worldwide rights to it. Bristol-Myers will pay Flamel $20 million now and $145 million when certain milestones are reached. It will also pay "double-digit royalties" to Flamel when and if the treatment hits the market. Flamel closed Wednesday at $26.95 on the Nasdaq. thestreet.com The pact needs antitrust approval.